I'm not much for technicals myself. I think that despite today's weak action, we are yet to see full appreciation for the back to back to back good news releases over the holiday period. Once everyone gets back from their vacations, and the good news percolates around a bit, then we should see a nice upward trend. I'm expecting a couple more upgrades too.
$14 by Jan 14!
I also think that we are now a legitimate take-out candidate. First offer at about $25.
Jack (James) I find your timing curious.
You pop back in here after a brief, but welcomed absence, and right after the long awaited FDA approval of P is announced, plus orphan status acceptance for 4161, and the PR announcing the start of 4430 P1 trials, just to impart your wisdom as to why BioCryst is overvalued at the current pps...actually predicting a fall to $5 in 6 months.
Curious, curious indeed...especially since you claim that you have no short position in the company and never have.
So I guess we are to believe that it's just out of the kindness of your own heart...
that you took time out of your busy schedule...
to impart your vast wisdom and insight...
about a company that you once backed 110%...
preached to all who would listen on this MB as to how undervalued they were... (let the bidding begin at $44 ring a bell?...and mind you...this was all well before the big 3 PR's from earlier this week)...
that you now...
feel so compelled to post how ridiculous it is to invest in an overvalued BioCryst!
All of this at the end of the biggest, most historically significant and positive week in the company's history!...hmmmm...
doesn't pass the sniff test Jack.
Happy Holidays Jack!
Sentiment: Strong Buy
Tekmira is strain specific so they have to create a new drug for each one. BCX4430 is broad spectrum making it the drug of choice post approval.
BTW, 4430 is now about 45 days into the PH1 safety trial. Stonehouse said back in Dec. he expected the trial to complete sometime between Feb. and April.
BCRX contracted with NIAID to manufacture about 2,000 doses to be ready by March for a possible field study.
Feb. 18 earnings call coming up quick...lots to be communicated.
Interesting, it allows for children and if I read it correctly CDC wants severly ill patients to receive 5 doses (600 mg) over 5 days.
2014–2015 Influenza Activity and
Clinician Outreach and
Communication Activity (COCA)
January 14, 2015
Angela Campbell, MD, MPH, FAAP
National Center for Immunization and Respiratory Diseases
Centers for Disease Control and Prevention
For patients who cannot tolerate or absorb oral
oseltamivir because of suspected or known
gastric stasis, malabsorption, or gastrointestinal
bleeding, the use of IV peramivir or
investigational IV zanamivir should be considered
If peramivir used in severely ill patients, single dose
should not be given
For severely ill patients, adult dose of 600 mg IV once
daily for 5 days is recommended (dose for children 6
years: 10 mg/kg once daily [up to 600 mg] for 5 days)
"you're flat out lying." yes indeed- your flat out lying, jacko.
(of a bad, difficult, or unwelcome situation or phenomenon) present or experienced to a severe or intense degree.
"Rapivab is a one-dose intravenous treatment for acute uncomplicated influenza in patients over the age of 18. It will typically be administered in hospitals and urgent care centers."
your a liar jack, the rest of your post is BS which i won't dignify with an answer. why don't you take your lying somewhere else like to little HS girls...
oh no…he's back…
hey jack, wanna see "a ridiculous call by you"? here's one-
"Biocryst won't sell one drop of Peramivir with out a partner.."
3. Peramivir: This is another form of antiviral treatment approved by the US Food and Drug Administration recently to fight the H1N1 pandemic. Unlike the tamiflu which is taken orally or relenza that’s inhaled, peramivir is injected intravenously to adult patients suffering from H1N1 influenza type A.
‘One advantage of this medication is that you just need one shot of injection and don’t have to follow up with a routine course of medication. However, this injection is available in the USA with a huge demand at the moment and has not reached the Indian shores yet. But we are hopeful,’ informs Dr Jiandani.
finviz has the best charts, as you can see the 2 hammers in the best format. chartists will see those 2 reversal's and tell you that this is one strong buy signal...
To be fair, Wood, BCRX has done amazingly well over the last 18 months – a period during which you were not invested in the stock, and also quite critical of her potential.
Roth Capital analyst Ed Arce maintained a Buy rating on BioCryst Pharmaceuticals (NASDAQ:BCRX) with a $20 price target, following the news that the FDA has granted the company’s BCX4161 its Fast Track designation, offering earlier and more frequent communication with the Agency.
BCX4161 is a novel, orally available selective inhibitor of plasma kallikrein, currently in an ongoing Phase 2b trial for the prevention of swelling attacks in patients with hereditary angioedema (HAE).
Arce noted, “Ultimately, we believe Rolling Review and Priority Review designations are also likely. Given the established unmet medical need in HAE, we believe the FDA may accept positive OPuS-2 data (expected by YE15) as a single pivotal trial for NDA submission (though we assume another trial), further accelerating ‘4161’s pathway to approval.”
• Emergency Department (ED)
• Observation Setting
• Hospital provider-based clinics
Physician offices include:
• Urgent Care Clinics
• Private practices
• Free-standing Infusion Centers
ALSO covered by some medicaid and private insurance companies.
One CODE on the reimbursement form refers to the following:
96365 Intravenous infusion, for therapy,
prophylaxis, or diagnosis; initial, up to 1 hour
This stock has buyout written all over it. The trading range has been so tight for months and months, despite times of market weakness and biotech surges. peramivir FDA approval with revenue and stockpiling potential plus the $100M+ cash they have, stellar HAE data + Ph2B in progress, the progress with 4430. Let's not forget the board of directors guy exercising 100k at 1.29 and not selling anything to pay for the exercise or taxes on the exercise.
This company should have been sold months ago with the HAE data but now with peramivir approved and 4430 progress and the cash plus the immense carried over quarterly losses that the acquiring company could use to minimize the cost by offsetting their own tax liability...it makes no sense for something not to happen here, especially with biotech M&A heating up here.
Jan 16, 2015, 11:23am CST UPDATED: Jan 16, 2015, 11:34am CST
Although the peak of flu season has yet to arrive, the Centers for Disease Control and Prevention are warning of "elevated" flu activity in all parts of the country, especially in the Southeast. There have been more than 5,000 cases reported since Oct. 1 of last year.
And just in time, the Birmingham laboratory of BioCryst Pharmaceuticals (Nasdaq: BCRX) has developed a new flu treatment that has recently gained approval from the U.S. Food and Drug Administration. It's the first new anti-viral flu treatment approved by the FDA in 15 years.
Originally designed for those who can't take oral drugs, Rapivab is a one-dose intravenous treatment for acute uncomplicated influenza in patients over the age of 18. It will typically be administered in hospitals and urgent care centers.
right jack. you just try to deceive anybody reading this forum, that's all…nobody here believes a word you say, because you lie, distort the truth, and somehow that's ok with you and your current position. PLEASE FOR THE LOVE OF GOD AND CONTRY GTFOH.
Fein noted, “While 2014 was mostly dominated by muted anxiety over a Form 483 hold on the contract manufacturer of Rapivab, FDA gave an official nod to the drug on December 19. By December 26, BCRX had Rapivab stocked at specialty distributers in time to begin tackling the current flu season, resulting in $33K in revenue recorded from product sale (and with $5.6M in deferred revenue representing the distributors’ kickoff stockpile). Beyond Rapivap sales through distributors for seasonal flu, we think the main focus of management in 2015 will shift toward securing a procurement contract with the government, which would generate significant non-dilutive cash for the company.”
Now that measles is becoming a story, it's interesting that BCX4430 in vitro was effective against it.
From Clear Science: "Amazingly, in vitro experiments showed that BCX4430 could potentially work against a wide range of viruses, including SARS, MERS, influenza, dengue, and measles"
PH1 human safety trial has been ongoing for about 1 month.